Maladaptive wound healing responses to chronic tissue injury result in organ fibrosis. Fibrosis, which entails excessive extracellular matrix (ECM) deposition and tissue remodeling by activated myofibroblasts, leads to loss of proper tissue architecture and organ function; however, the molecular mediators of myofibroblast activation have yet to be fully identified.
a r t i c l e s Dysregulated wound repair processes can lead to the development of tissue fibrosis in most organs. Fibrosis is characterized by excess accumulation of collagens and other matrix proteins that results in the distortion of tissue architecture and ultimately organ failure in a variety of human diseases, including idiopathic pulmonary fibrosis (IPF) and systemic sclerosis (SSc, scleroderma) 1 . This pathological accumulation of matrix proteins is attributable to the excess recruitment of fibroblasts to sites of tissue injury and/or to their excessive activation to an effector myofibroblast phenotype [1] [2] [3] [4] [5] . We have previously found increased expression of genes associated with cell migration and myofibroblast activation in the lungs of individuals with IPF with a more rapidly advancing clinical course, leading us to hypothesize that this set of genes contributes to IPF progression 6 . If so, elucidating the regulation of fibroblast migration and activation will not only further enhance our understanding of the pathogenesis of fibrosis but will also provide targets for new antifibrotic therapies.
To identify putative genes that regulate profibrotic fibroblast functions, we analyzed a publicly available microarray data set comparing the gene expression of lung fibroblasts isolated from individuals with IPF or SSc-associated interstitial lung disease (SSc-ILD) to that of healthy lung fibroblasts used as controls 7 . Among the genes upregulated in fibroblasts from both individuals with IPF and with SSc-ILD in this data set, we found EFNB2 (Gene Expression Omnibus accession number GSE1724; EFNB2 probe: 34334_at) 7 . EFNB2 encodes the transmembrane protein ephrin-B2, which belongs to the family of ephrin ligands and has previously been described as exhibiting promigratory activities 8, 9 . Ephrins are glycosyl-phosphatidylinositollinked (ephrin-A1-6) and transmembrane (ephrin-B1-3) cell surface ligands that bind to Eph receptors at the surface of adjacent cells. This interaction initiates bidirectional signaling events between the receptor-expressing (forward signaling) and ligand-expressing (reverse signaling) cells 10 . Ephrin-Eph signaling controls tissue patterning a r t i c l e s and cell motility during embryonic development 11 . In accordance with its promigratory activities, the ephrin-B2 ligand, which signals through EphB receptors, also controls cell motility and adhesion during assembly of the blood vessel wall 9, 12, 13 . Genetic inactivation of Efnb2 in smooth muscle cells and pericytes during development results in disrupted microvessel architecture and increased vascular permeability in mice 9 . Mice lacking the intracellular PDZ signaling domain of ephrin-B2, in which reverse signaling by ephrin-B2 is consequently attenuated, have compromised vascular stabilization by pericytes, resulting in increased capillary rarefaction and fibrosis after kidney injury 14 . In human disease, ephrin-B2 expression is increased in small vessels and in vascular smooth muscle in clinically involved skin of individuals with SSc 15 . Although ephrin-B2 signaling has been implicated in vascular contributions to the development of fibrosis in mouse models and human disease, the full spectrum of cellular and molecular mechanisms through which ephrin-B2 signaling may contribute to the development of tissue fibrosis has not been investigated. Here we describe a new mechanism through which ADAM10-mediated proteolytic shedding of the ephrin-B2 ectodomain, herein referred to as sEphrin-B2, promotes fibroblast recruitment and activation. We provide molecular, genetic, functional and translational evidence that this mechanism plays an important role in fibroblast activation in vitro and in the development of the lung and skin fibrosis in vivo.
RESULTS

Bleomycin-induced lung fibrosis requires ephrin-B2 in fibroblasts
Our initial studies confirmed that expression of ephrin-B2, but not other members of the ephrin family of ligands, is markedly higher in lung fibroblasts isolated from individuals with IPF compared with that in lung tissue from control subjects, as demonstrated by mRNA and protein analyses ( Fig. 1a,b) . We then investigated whether fibroblast ephrin-B2 is required for the development of fibrosis in vivo. As mice that are globally ephrin-B2-deficient die at midgestation owing to defective cardiovascular development 13, 16 , we generated mice in which we could conditionally delete Efnb2 in collagen-expressing cells, such as fibroblasts. We crossed mice with Efnb2 flanked by loxP sites (Efnb2 loxP/loxP mice) 17 to mice that express a tamoxifen-inducible Cre recombinase driven by the mouse promoter of Col1a2 (collagen, type I, alpha 2) (Col1a2-Cre ERT mice) ( Fig. 1c) . Tamoxifen treatment of offspring that were homozygous for the 'floxed' Efnb2 allele and hemizygous for the Col1a2-Cre transgene (Efnb2 loxP/loxP ; Col1a2-Cre ERT mice), as confirmed by PCR ( Fig. 1d) , led to the deletion of the Efnb2 gene in fibroblasts and the generation of Efnb2 conditional knockout mice, herein referred to as Ephrinb2-CKO mice. Littermates treated with corn oil vehicle alone were used as controls and are herein referred to as Ephrinb2-C mice. Western blotting for ephrin-B2 protein demonstrated markedly lower expression in extracts from lung fibroblasts of Ephrinb2-CKO mice compared to those from Ephrinb2-C mice. We observed preservation of Ephrin-B2 protein in extracts from alveolar macrophages in Ephrinb2-CKO mice compared to those from Ephrinb2-C mice (Fig. 1e) . We also isolated alveolar epithelial cells from Ephrinb2-C and Ephrinb2-CKO mice, but we did not observe ephrin-B2 protein expression by western blotting in these cells from Ephrinb2-C mice, and thus we could not compare its potential preservation in alveolar epithelial cells from Ephrinb2-CKO mice.
Ephrinb2-CKO and Ephrinb2-C mice were then challenged with intratracheal bleomycin or PBS (Fig. 1f) . Blinded histological analysis revealed that the lung parenchymal fibrosis observed in Ephrinb2-C at 14 d following bleomycin challenge was markedly lower than that in Ephrinb2-CKO mice, which was associated with substantially lower lung hydroxyproline (collagen) content ( Fig. 1g,h) . Further, evaluation of fibrotic protein markers in total lung homogenates showed markedly lower expression of both αsmooth muscle actin (α-SMA, a marker of myofibroblast differentiation) and type I collagen in bleomycin-challenged Ephrinb2-CKO mice compared to controls (Fig. 1i) .
Identification of soluble ephrin-B2 ectodomain in bronchoalveolar lavage fluid
Considering the requirement for ephrin-B2 fibroblast expression that we identified in bleomycin-induced lung fibrosis, we next investigated the regulation of ephrin-B2 expression in this model. Lung homogenates taken from wild-type (WT) mice at 14 d following bleomycin challenge did not demonstrate greater expression of the full-length transmembrane ephrin-B2 (approximately 60 kDa, as previously described for fibroblasts, endothelial cells and cancer cells 18 ) compared to homogenates from WT mice following PBS challenge; however, a lower-molecular-weight band (~50 kDa) appeared in the homogenates following bleomycin challenge that was either absent or expressed at low levels in lungs following PBS challenge ( Fig. 2a) .
Ephrin-B ligands, as well as EphB receptors, have been shown to undergo ectodomain shedding to release active proteins [19] [20] [21] [22] . Proteolytic cleavage of mouse ephrin-B2 has recently been shown to generate a 50-kDa band corresponding to the ectodomain of ephrin-B2, consistent with our findings in Figure 2a 23 . These data led us to hypothesize that ephrin-B2 is proteolytically cleaved following profibrotic lung injury and that the resulting sEphrin-B2 contributes to the pathogenesis of fibrosis. To investigate this hypothesis, we first evaluated the presence of sEphrin-B2 in bronchoalveolar lavage (BAL) following bleomycin challenge. As demonstrated by western blotting with an N-terminus-specific anti-ephrin-B2 antibody, sEphrin-B2 expression was observed at low basal levels in BAL from WT mice 14 d following PBS treatment but was markedly greater in BAL from WT mice 14 d following bleomycin challenge (Fig. 2b,c) . Further, using an enzyme-linked immunosorbent assay (ELISA) with an ectodomain-specific anti-ephrin-B2 detection monoclonal antibody (mAb), we observed greater sEphrin-B2 concentration in BAL from bleomycin-challenged mice at 3, 7 and 14 d following bleomycin challenge compared to PBS-challenged mice ( Fig. 2d) .
Oligomeric sEphrin-B2 directs fibroblast migration, invasion and myofibroblast differentiation
To investigate whether generation of sEphrin-B2 was reduced in Ephrinb2-CKO mice following bleomycin challenge, which could contribute to the protection of these mice from lung fibrosis in this model, we compared the concentrations of sEphrin-B2 in BAL of Ephrinb2-CKO and Ephrinb2-C in mice 14 d following bleomycin treatment. sEphrin-B2 concentration was lower, but not completely eliminated, in BAL from Ephrinb2-CKO mice compared to Ephrinb2-C mice 14 d following bleomycin treatment ( Fig. 2e) . We hypothesized that this reduction was at least in part attributable to loss of sEphrin-B2 generation from ephrin-B2-deficient fibroblasts: i.e., that fibroblasts in WT mice are a source of the sEphrin-B2 generated in response to lung injury. To test this hypothesis, we used ELISA to assess sEphrin-B2 shedding by lung fibroblasts isolated from PBS-or bleomycin-challenged WT mice. A low concentration of sEphrin-B2 was present in medium conditioned by lung fibroblasts isolated from PBS-challenged WT mice. In contrast, medium conditioned by © 2017 Nature America, Inc., part of Springer Nature. All rights reserved. a r t i c l e s nature medicine VOLUME 23 | NUMBER 12 | DECEMBER 2017 1 4 0 7 lung fibroblasts isolated from WT mice 7 d following bleomycin challenge had a markedly higher concentration of sEphrin-B2 ( Fig. 2f) . Furthermore, the concentration of sEphrin-B2 was substantially lower in medium conditioned by lung fibroblasts isolated from PBS-or bleomycin-challenged fibroblasts that had been transfected with small interfering RNA (siRNA) targeting ephrin-B2 compared to medium conditioned by these fibroblasts transfected with nontargeting control siRNA ( Fig. 2f) .
We next determined whether the ephrin-B2 ectodomain that is shed as sEphrin-B2 from fibroblasts and present in BAL following lung injury directs profibrotic activities of fibroblasts. In these experiments, we used recombinant mouse ephrin-B2-Fc, which contains the ectodomain of ephrin-B2 fused to an Fc domain that replaces the transmembrane and C-terminal domains of the full-length ephrin-B2 protein (Fig. 3a) . Structural and functional studies have demonstrated that EphB receptor activation requires a r t i c l e s higher-order ephrin-B2 oligomers 24 ; we consequently preclustered ephrin-B2-Fc for these experiments by incubating mouse ephrin-B2-Fc with IgG antibody in a 2:1 ratio immediately before use. Treatment of mouse lung fibroblasts with preclustered ephrin-B2-Fc, but not preclustered ephrin-B1-Fc or ephrin-B3-Fc, markedly increased filopodia formation (Fig. 3b,c) , suggesting that ephrin-B2, but not ephrin-B1 or ephrin-B3, can regulate fibroblast motility. Chemotaxis assays demonstrated that preclustered ephrin-B2-Fc induced fibroblast migration in a dose-dependent manner similar to chemotactic agents, such as lysophosphatidic acid (LPA) or platelet-derived growth factor (PDGF-BB) ( Fig. 3d) . These findings indicate that sEphrin-B2 contributes to fibroblast chemotaxis. The ephrin-B2 ligand signals through the EphB subfamily of receptor tyrosine kinases, which includes EphB1-4 and EphB6 (EphB5 is present in chickens, but no mammalian homolog has been identified) 25 . Primary mouse lung fibroblasts expressed Ephb2, Ephb3 and Ephb4 mRNA, but not Ephb1 or Ephb6 mRNA ( Fig. 3e) . Individual siRNA knockdown of these receptors revealed that both fibroblast chemotaxis and fibroblast invasion through Matrigel induced by BAL from bleomycin-treated mice required both EphB3 and EphB4 (EphB3/4), but not EphB2, receptor signaling ( Fig. 3f,g) .
Lung fibroblasts
As EphB receptor activation requires higher-order ephrin-B2 oligomers, as noted above 24 , we investigated the quaternary structure of sEphrin-B2 in BAL by immunoblotting BAL proteins that had been separated by native PAGE on nonreducing gels. Our N-terminusspecific anti-ephrin-B2 mAb recognized high-molecular-weight species consistent with higher-order sEphrin-B2 oligomers in BAL from bleomycin-challenged, but not control, mice (Fig. 3h) . These higher-order species were not recognized in BAL samples pretreated with SDS and 2-mercaptoethanol, further indicating that sEphrin-B2 is present in the form of higher-order oligomers in BAL recovered from mice following lung injury. Results from competition studies performed by preincubating our N-terminus-specific anti-ephrin-B2 mAb with recombinant ephrin-B2 before immunoblotting were consistent with those expected from this antibody binding to sEphrin-B2 in the oligomers (Supplementary Fig. 1 ). Our results suggest that sEphrin-B2 oligomers are present in BAL following lung injury and are biologically active in that they are able to mediate profibrotic functions of fibroblasts. In accordance with this hypothesis, depletion of sEphrin-B2 in BAL from bleomycin-challenged mice with magnetic beads coated with the N-terminus-specific anti-ephrin-B2 mAb markedly, though not completely, reduced the fibroblast chemotaxis that was induced by these BAL samples ( Fig. 3j) .
We next determined whether ephrin-B2 signaling could also induce fibroblast-to-myofibroblast differentiation. Treatment of primary mouse lung fibroblasts with preclustered ephrin-B2-Fc markedly increased Acta2 and Col1a1 mRNA and α-SMA and type I collagen protein expression compared to IgG-Fc treatment ( Fig. 3k,l) .
Treatment with Ephrin-B2 ectodomain is sufficient to drive tissue fibrosis in vivo As ephrin-B2 ectodomain can direct profibrotic fibroblast functions in vitro, we next investigated whether recombinant ephrin-B2-Fc can induce tissue fibrosis in vivo. Mice were injected subcutaneously with preclustered mouse ephrin-B2-Fc (100 µg per kg body weight per mouse) or IgG-Fc as a control daily for 2 weeks. Blinded histological analysis showed that ephrin-B2-Fc treatment produced robust dermal fibrosis ( Fig. 3m ) associated with markedly increased dermal thickness ( Fig. 3n) , hydroxyproline content ( Fig. 3o ) and α-SMA and type I collagen expression ( Fig. 3p ) as compared to the results of IgG-Fc treatment. Although these data demonstrate that ephrin-B2 forward signaling by the ephrin-B2 ectodomain is sufficient to drive myofibroblast formation and tissue fibrosis in vivo, we have not investigated potential contributions of this ectodomain on other cell types, such as endothelial or immune cells.
In addition to lung fibrosis, we assessed the role of ephrin-B2 in the development of skin fibrosis in vivo. We subjected Ephrinb2-CKO mice and Ephrinb2-C mice to the bleomycin model of dermal fibrosis ( Fig. 3q) . Blinded histological analysis showed markedly attenuated skin fibrosis in bleomycin-treated Ephrinb2-CKO mice, which was 3.00
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Ephrin-B2 (µg) Chemotactic index a r t i c l e s associated with considerably lower dermal thickness and hydroxyproline content compared to control mice (Fig. 3r,s) .
Identification of ADAM10 as the ephrin-B2 ectodomain sheddase in fibroblasts
Previous studies have shown that ephrins can be cleaved by metalloproteinases, including matrix metalloproteinases (MMPs) and ADAMs [19] [20] [21] [22] . In order to investigate whether shedding of the ephrin-B2 ectodomain is regulated by metalloproteinases in fibroblasts, we tested the ability of BB-94, a broad-spectrum inhibitor of both MMPs and ADAMs, to inhibit fibroblast generation of sEphrin-B2. BB-94 treatment reduced sEphrin-B2 concentration in medium conditioned by healthy human lung fibroblasts in a dose-dependent manner, indicating that metalloproteinase(s) contribute to ephrin-B2 cleavage ( Fig. 4a) . Of the MMPs and ADAMs, these fibroblasts expressed MMP1, MMP2 and MMP14, as well as ADAM9, ADAM10, ADAM12 and ADAM17 (Fig. 4b) .
In order to investigate whether any of these proteases act as ephrin-B2 ectodomain sheddases in human lung fibroblasts, we performed siRNA knockdowns of each of these metalloproteinases individually. We first confirmed that siRNA duplexes efficiently knocked down the MMPs and ADAMs that we found to be expressed by cultured primary human lung fibroblasts ( Supplementary Fig. 2 ). We then found that siRNA-mediated knockdown of ADAM10, but not the other genes encoding ADAMs or MMPs expressed by fibroblasts, markedly lowered sEphrin-B2 concentration in fibroblast cell culture supernatant as assessed by ELISA ( Fig. 4c) .
To further investigate whether ADAM10 is responsible for ephrin-B2 ectodomain shedding in fibroblasts, we used phorbol 12-myristate 13-acetate (PMA), which activates limited proteolysis of membranebound proteins, i.e., ectodomain shedding, by increasing the activity of ADAM10 and ADAM17 (ref. 26 ). Treatment of human lung fibroblasts with PMA for 30 min resulted in a marked increase in the sEphrin-B2 concentration in fibroblast cell culture supernatants compared to that from fibroblasts treated with DMSO as control ( Fig. 4c) . Knockdown of ADAM10 by siRNA also substantially reduced sEphrin-B2 concentration in medium conditioned by PMA-stimulated fibroblasts, whereas knockdown of ADAM17 or genes encoding other ADAMs or MMPs had no pronounced effects compared to human lung fibroblasts transfected with nontargeting siRNA. Moreover, treatment of fibroblasts with GI254023X, an ADAM10specific inhibitor, reduced both constitutive and PMA-stimulated sEphrin-B2 concentration in fibroblast supernatants in a dosedependent manner (Fig. 4d) . In contrast, fibroblast treatment with TAPI-0, an ADAM17-specific inhibitor, did not prevent sEphrin-B2 generation by fibroblasts ( Fig. 4d) , further implicating ADAM10 in ephrin-B2 shedding.
ADAM10-mediated ephrin-B2 shedding drives TGF-b-induced myofibroblast activation
Having identified ADAM10 as the major sheddase of the ephrin-B2 ectodomainin fibroblasts, we then investigated the regulation of this shedding, and its contribution to the profibrotic activities of these cells. TGF-β1 is a prototypical profibrotic cytokine that induces myofibroblast activation 27, 28 . Whereas TGF-β1 treatment of human lung fibroblasts did not induce expression of EFNB2 mRNA, it did result in greater ADAM10 mRNA expression in these cells as compared to untreated cells ( Fig. 4e) and in a substantially greater sEphrin-B2 concentration in medium conditioned by these cells compared to that conditioned by untreated cells (Fig. 4f) .
Considering that we found that recombinant ephrin-B2-Fc induced fibroblast differentiation into activated myofibroblasts in vitro and resulted in greater expression of the myofibroblast marker α-SMA in mice in vivo, we investigated whether TGF-β-induced myofibroblast activation is dependent on ephrin-B2 shedding. Genetic knockdown of ADAM10 or pharmacological inhibition with the ADAM10-selective inhibitor GI254023X 29 reduced TGF-β-induced sEphrin-B2 production, confirming the role of ADAM10 in TGF-βinduced ephrin-B2 shedding (Fig. 4f,g) . TGF-β-induced expression of the α-SMA protein by human lung fibroblasts was also markedly reduced by siRNA knockdown of ADAM10 (Fig. 4h) or by pharmacological inhibition of ADAM10 with GI254023X, which reduced TGFβ-induced ACTA2 mRNA expression dose-dependently ( Fig. 4i) . GI254023X treatment also markedly and dose-dependently reduced TGF-β-induced α-SMA protein expression by human lung fibroblasts ( Fig. 4j) . Further, immunofluorescence staining of human lung fibroblasts with an anti-α-SMA antibody and rhodamine-phalloidin demonstrated that GI254023X treatment inhibited TGF-β-induced formation of stress fibers and incorporation of α-SMA protein into stress fibers, which are both phenotypic characteristics of activated myofibroblasts (Fig. 4k) . Taken together, these results indicate that TGF-β-induced myofibroblast formation requires ADAM10-mediated ephrin-B2 shedding.
Previous studies have shown that ADAM10 cleaves ephrin-B2 in the juxtamembrane region of its ectodomain 20, 30 (Fig. 4l) . We therefore tested whether this region is important for TGF-β-induced ephrin-B2 shedding and myofibroblast activation. Forced overexpression of ephrin-B2 ∆Ecto , which lacks the entire ephrin-B2 ectodomain but preserves the transmembrane and intracellular domains, markedly reduced the amount of sEphrin-B2 produced by these cells in response to TGF-β compared to that produced by TGF-β challenge of fibroblasts transfected with WT ephrin-B2 (Fig. 4l,m) . Likewise, overexpression of a mutant with a deletion of the juxtamembrane region, ephrin-B2 ∆Juxta , which lacks amino acids 168-218 of the ephrin-B2 ectodomain, abrogated TGF-β-induced ephrin-B2 shedding (Fig. 4l,m) . Further, deletions of specific sequences in the juxtamembrane region (amino acids 182-194 or 197-218) rendered ephrin-B2 resistant to TGF-β-induced ephrin-B2 shedding ( Fig. 4l,m) .
To further demonstrate that the juxtamembrane region of ephrin-B2 is required for ephrin-B2 shedding induced by TGF-β, we analyzed ephrin-B2 protein levels in fibroblasts transfected with hemagglutinin (HA)-tagged WT ephrin-B2 or HA-tagged, cleavage-resistant mutants. As shown in Figure 4n , the amount of HA-tagged WT ephrin-B2 that was detected by anti-HA antibodies in lysates of human lung fibroblasts was substantially reduced by TGF-β treatment; this result is in accordance with TGF-β-induced ephrin-B2 shedding. In contrast, this TGF-β-induced reduction in HA-tagged ephrin-B2 expression was largely prevented in human lung fibroblasts overexpressing HAtagged, cleavage-resistant ephrin-B2 mutants, further demonstrating that the juxtamembrane region of ephrin-B2 is required for ectodomain cleavage (Fig. 4n) .
We next investigated whether overexpression of cleavage-resistant ephrin-B2 mutants prevents TGF-β-mediated myofibroblast activation, in addition to ephrin-B2 shedding. We found that human lung fibroblasts overexpressing cleavage-resistant ephrin-B2 mutants had reduced TGF-β-induced ACTA2 mRNA and α-SMA protein levels compared to human lung fibroblasts transfected with WT ephrin-B2 (Fig. 4o,p) , in accordance with a requirement for ephrin-B2 cleavage for TGF-β-induced myofibroblast activation. a r t i c l e s As expression of the recombinant ephrin-B2 ectodomain was sufficient to drive myofibroblast activation and TGF-β-induced myofibroblast activation required ADAM10-mediated ephrin-B2 shedding, we hypothesized that TGF-β-induced myofibroblast activation is controlled by autocrine sEphrin-B2-EphB receptor signaling. Of the five identified EphB receptors, primary human lung fibroblasts expressed proteins encoded by EPHB3 and EPHB4, but not EPHB1, EPHB2 or EPHB6 (Fig. 4q) . We found that siRNA-mediated knockdown of EPHB3 or EPHB4 markedly reduced the TGF-β-induced increase in both ACTA2 mRNA and α-SMA protein levels compared to human lung fibroblasts transfected with nontargeting siRNA (Fig. 4r,s) , demonstrating that both receptors mediate profibrotic activities of sEphrin-B2 in lung fibroblasts.
Pharmacological inhibition of ADAM10 prevents bleomycininduced lung fibrosis in mice
On the basis of our findings above, we hypothesized that therapeutic targeting of ADAM10 with the ADAM10-selective pharmacological inhibitor GI254023X 29 could prevent lung fibrosis by inhibiting ephrin-B2 shedding and myofibroblast activation in vivo. Previous studies show that bleomycin challenge rapidly increases levels of activated TGF-β within areas of lung injury 31, 32 , which led us to hypothesize that ADAM10 levels would be similarly increased upon lung injury. Indeed, ADAM10 expression levels were markedly higher in vivo after bleomycin-induced lung injury compared to those in PBS-challenged mice (Fig. 5a) . To examine the ability of ADAM10 inhibition to mitigate lung fibrosis in vivo, mice were subjected to the bleomycin-induced lung fibrosis model and treated daily with GI254023X (200 mg per kg body weight per day) or vehicle control by intraperitoneal injection. Blinded histological analysis revealed that the lung parenchymal fibrosis produced 14 d following bleomycin challenge in vehicle-treated mice was mitigated in mice treated with GI254023X (Fig. 5b) , and this was associated with marked reduction in lung hydroxyproline levels (Fig. 5c ). ADAM10 inhibition also resulted in a considerably lower level of α-SMA expression in bleomycin-challenged mice compared to PBS-challenged mice (Fig. 5d) .
To gain insight into the mechanism of action of GI254023X in this lung fibrosis model, we assessed sEphrin-B2 concentration in BAL samples. In accordance with our in vitro studies demonstrating that ADAM10 is responsible for ephrin-B2 cleavage to generate sEphrin-B2, GI254023X treatment reduced sEphrin-B2 concentration in the BAL of bleomycin-challenged mice (Fig. 5e) , suggesting that the ADAM10-sEphrin-B2 axis drives myofibroblast activation in lung fibrosis in vivo. Further, ADAM10 inhibition with GI254023X markedly reduced mortality caused by bleomycin-induced lung injury and fibrosis in mice (Fig. 5f) .
ADAM10-sEphrin-B2 signaling is upregulated in idiopathic pulmonary fibrosi
To determine the relevance of our studies to human disease, we investigated the role of ADAM10-sEphrin-B2 signaling in fibroblasts isolated from the lungs of individuals with IPF and healthy controls. IPF lung fibroblasts had a substantially higher concentration of sEphrin-B2 in culture medium and expressed markedly increased ADAM10 mRNA compared to normal lung fibroblasts in vitro (Fig. 6a,b) . Pharmacological inhibition of ADAM10 with GI254023X or siRNA knockdown of ADAM10 markedly reduced sEphrin-B2 production by both IPF and control lung fibroblasts (Fig. 6c,d) , confirming that ADAM10 is responsible for ephrin-B2 shedding in IPF and control lung fibroblasts. IPF lung fibroblasts are characterized by increased type I collagen and α-SMA expression 33 . We examined whether ADAM10-sEphrin-B2 signaling contributes to this increased expression of COL1A1 and ACTA2 through inhibition of ADAM10 in IPF lung fibroblasts. Treatment with GI254023X or a siRNA targeting ADAM10 markedly inhibited the increased COL1A1 and ACTA2 expression of IPF fibroblasts compared to controls ( Fig. 6e-h) .
Considering the relevance of the ADAM10-sEphrin-B2 axis in IPF lung fibroblasts, we next examined concentration of sEphrin-B2 in both BAL fluid and plasma samples from individuals with IPF and healthy volunteers. Quantification of sEphrin-B2 in these samples by ELISA and by western blotting of a subset of these samples showed a markedly increased concentration of sEphrin-B2 in the BAL fluid of 16 individuals with IPF compared to samples from 8 healthy volunteers (Fig. 6i,j) . We then compared plasma sEphrin-B2 concentration in 30 individuals with IPF and 30 gender-matched, nonsmoking controls (subject demographics in Supplementary Table 1 ) Supplementary Figure 8. (l) Schematic of the working model of ADAM10mediated ephrin-B2 shedding in fibroblasts. Our results suggest that in fibroblasts during the development of fibrosis, sEphrin-B2 is produced by ADAM10 upregulation in TGF-β-stimulated fibroblasts. sEphrin-B2 then acts through EphB3/4 receptors to further drive and/or amplify profibrotic fibroblast effector functions, including migration, invasion, myofibroblast differentiation and extracellular matrix production in an autocrine and/or paracrine fashion. a r t i c l e s and observed a markedly higher concentration of plasma sEphrin-B2 in the individuals with IPF compared to the samples from the control group (Fig. 6k) .
DISCUSSION
Using a combination of mouse models and clinical samples obtained from individuals with IPF, we demonstrate that a soluble form of ephrin-B2, composed of its cleaved ectodomain, is a potent mediator of tissue fibrosis. This soluble form, sEphrin-B2, was markedly elevated in the lung tissue and the BAL of mice in our pulmonary fibrosis model and in the BAL of individuals with IPF, suggesting ephrin-B2 shedding is increased in response to tissue injury. We demonstrate that treatment with recombinant Ephrin-B2 ectodomain was sufficient to induce dermal fibrosis in mice when injected subcutaneously by promoting collagen and α-SMA expression consistent with that of myofibroblast activation. Conversely, loss of ephrin-B2 in the fibroblasts of mice resulted in decreased sEphrin-B2 generation and protection from lung and dermal fibrosis in vivo, identifying ephrin-B2 as a critically important profibrotic mediator. Although loss of ephrin-B2 in fibroblasts provided substantial protection from bleomycin-induced skin and lung fibrosis, we did not observe full protection in both models, suggesting additional cell types, such as inflammatory cells, may also be sources of sEphrin-B2 during the development of tissue fibrosis, which will be the focus of future investigations. It has previously been demonstrated that both ephrin-B ligands and EphB receptors undergo ectodomain shedding to release active proteins [19] [20] [21] [22] . In cancer cells, shedding of membrane-bound ephrin-B ligands regulates invasion 34 . To the best of our knowledge, however, our study is the first to describe ephrin-B2 shedding in tissue fibrosis and to implicate sEphrin-B2 in human fibrotic disease. Our results suggest a new regulatory mechanism, through which proteolytic shedding of the ectodomain of ephrin-B2 amplifies myofibroblast activation and profibrotic functions, occurs during tissue fibrogenesis. Our studies demonstrate that the generation of sEphrin-B2 by fibroblasts induced ephrin-B2 forward signaling through EphB3/4, which is involved in multiple fibroblast functions, including migration, invasion, myofibroblast differentiation and collagen production.
Our study also identified ADAM10 as the major metalloprotease responsible for the generation of sEphrin-B2 by human lung fibroblasts. Ephrin-B2 cleavage by ADAM10 has recently been demonstrated during Xenopus development 20 , suggesting that there is an evolutionarily conserved mechanism for ephrin-B2 cleavage by ADAM10 in both development and tissue fibrogenesis. The aberrant reactivation of multiple developmental pathways has been implicated in the pathogenesis and progression of lung fibrosis 35, 36 , and our results indicate that ADAM10-ephrin-B2 may be another such pathway. Consistently, our results suggest that the ADAM10-mediated ephrin-B2 shedding pathway is reactivated by tissue injury, and its sustained activation promotes organ fibrosis by sustaining and amplifying myofibroblast activation.
We also identified EphB3/4 as the receptors through which the ADAM10-sEphrin-B2 pathway directs myofibroblast activation. Importantly, our results demonstrate that sEphrin-B2 produced in the alveolar space upon lung injury is the form of active high-molecular -weight oligomers. Activation of forward EphB receptor signaling requires Eph receptor clustering induced by binding of oligomeric ephrins. Our results demonstrate that this oligomeric state of sEphrin-B2 in fibrotic tissues is biologically active and regulates myofibroblast functions. Consequently, strategies to interrupt the elaboration of sEphrin-B2 by fibroblasts by targeting ADAM10 have the potential to serve as new therapeutic strategies for fibrotic diseases. As we found, therapeutic targeting of ADAM10 with GI254023X was able to substantially reduce lung fibrosis in mice by inhibiting ephrin-B2 shedding and myofibroblast activation in vivo, providing preclinical evidence that inhibition of ADAM10 could mitigate fibrosis in vivo.
During our investigations into the molecular mechanism(s) through which ADAM10-mediated ephrin-B2 shedding is activated in fibroblasts, we determined that this pathway was activated by TGF-β, the prototypical cytokine that drives myofibroblast activation. We found that fibroblast ADAM10 expression, but not expression of ephrin-B2 itself, is induced by TGF-β signaling. Further, we found that genetic or pharmacological inhibition of ADAM10mediated ephrin-B2 shedding blocks myofibroblast activation by TGF-β, indicating that ephrin-B2 cleavage is required for the generation of myofibroblasts, which are central effector cells in the development of fibrosis. Currently, it is not fully understood how ADAM10 mediates ephrin-B2 cleavage in fibroblasts. Previous studies have shown that ADAM10 cleaves the juxtamembrane regions of ephrin-A2 (ref. 22 ) and ephrin-B2 (ref. 20) to release active ectodomains. Consistent with these data, our genetic studies overexpressing cleavage-resistant ephrin-B2 mutants confirmed the requirement for the juxtamembrane region of ephrin-B2 in ADAM10-mediated ephrin-B2 shedding and myofibroblast activation by TGF-β. The molecular requirement for ADAM10-mediated ephrin-B2 shedding in myofibroblast activation by TGF-β warrants further investigation. Previous studies have shown that ephrin-B2 and EphB4 receptor interact on the surface of the same cell (i.e., 'in cis'), and this interaction attenuates the ability of ephrin-B2 expressed in other cells to activate forward ephrin-B2-EphB4 receptor signaling 'in trans' 37 . Our studies on human lung fibroblasts may suggest a molecular mechanism through which high expression of membrane-bound ephrin-B2 in quiescent fibroblasts prevents activation of forward EphB3/4 receptor signaling via cis negative interaction. Upon tissue injury, TGF-β-mediated ADAM10 upregulation would lead to increased ephrin-B2 shedding in activated myofibroblasts. Consequently, ADAM10-mediated ephrin-B2 shedding could promote (a) de-repression of the negative cis inhibitory ephrin-B2-EphB3/4 receptor interaction and/or (b) activation of profibrotic forward EphB3/4 receptor signaling activated by autocrine sEphrin-B2, although ephrin-B2 expressed in other cells implicated in pathological fibrosis could be involved in activation of EphB3/4 receptors in trans. Further research focused on gathering mechanistic understanding of ephrin-B2 signaling in activated myofibroblasts is needed.
Although our study does not address whether ephrin-B2 reverse signaling may also regulate myofibroblast activation or function, ephrin-B2 ectodomain shedding would concomitantly terminate ephrin-B2 reverse signaling through the cytoplasmic tail of ephrin-B2 in fibroblasts previously bearing full-length ephrin-B2. Reverse ephrin-B2 ligand signaling has recently been shown to play an antifibrotic role in mouse models of kidney fibrosis protecting against peritubular capillary rarefaction through promotion of angiogenesis and vascular stability during kidney injury and, most relevant to our study, through inhibition of pericyte-to-myofibroblast transition and myofibroblast activation 14 . Thus ephrin-B2 ectodomain shedding may not only promote myofibroblast activation through promotion of profibrotic ephrin-B2 forward signaling but also by terminating antifibrotic ephrin-B2 reverse signaling.
Our studies also show that ADAM10-sEphrin-B2 signaling is upregulated in fibroblasts from individuals with IPF and an elevated concentration of sEphrin-B2 in plasma and in BAL from individuals © 2017 Nature America, Inc., part of Springer Nature. All rights reserved. a r t i c l e s nature medicine VOLUME 23 | NUMBER 12 | DECEMBER 2017 1 4 1 5
with IPF. These data further emphasize on the relevance of ADAM10-sEphrin-B2 signaling in human disease.
In summary, we have identified a new pathway that promotes myofibroblast activation and effector functions through cleavage of ephrin-B2 by ADAM10 to generate sEphrin-B2 that signals through EphB3/4. This pathway is required for TGF-β-induced myofibroblast activation, suggesting it plays a central role in the pathogenesis of fibrotic diseases. Our study also identifies sEphrin-B2, its receptors EphB3/4 and its sheddase ADAM10 as potential therapeutic targets for this class of diseases (Fig. 6l) .
METHODS
Methods, including statements of data availability and any associated accession codes and references, are available in the online version of the paper. or BAL fractions, ephrin-B2-Fc, 18:1 LPA (Avanti Polar Lipids) or PDGF-BB (R&D Systems) as chemoattractants. The plate was then incubated for 4 h at 37 °C in a 5% CO 2 atmosphere. Fluorescence of migrated cells was recorded at 544/590 nm (Ex/Em) on a bottom-reading fluorescent plate reader using Fluoroskan Ascent FL (Thermo). The data were expressed as the ratio of migrated cells toward any chemoattractant to cells migrated toward serum-free DMEM. Experiments were performed in triplicate. For invasion assays, a 96-well BioCoat Tumor Invasion System (Fisher Scientific) was used, and the plate was read at 48 h. Cells at passages 3 to 5 were used for chemotaxis and invasion assays. To test the effect of receptor inhibition, fibroblasts were transfected with siRNA to EPHB2, EPHB3 or EPHB4 before addition of BAL as a chemoattractant.
siRNA and plasmid transfection. The siRNA duplexes targeting human ephrin-B2, human MMP1, human MMP2, human MMP7, human MMP14, human ADAM9, human ADAM10, human ADAM12, human ADAM17, human ADAM19, human EPHB3, human EPHB4, mouse ephrin-B2, mouse Ephb2, mouse Ephb3 and mouse Ephb4 mRNA were On-Target Plus Smart Pools and were obtained from Dharmacon Inc. (Thermo Scientific). The siRNAs (20 nM) were transiently transfected into human and mouse primary fibroblasts using HiPerFect Reagent (Qiagen) at a siRNA/HiPerFect ratio of 1:4 (µg/µl). siRNAs from the On-Target Plus nontargeting siRNA pool were used as a nonspecific control. Cells were harvested and mRNA levels were assessed 48 h after transfection. Transient transfection experiments with ephrin-B2 mutants were performed on primary human and mouse lung fibroblasts seeded on 6-well plates (60-70% confluency) using Lipofectamine 2000 (Thermo Fisher Scientific). RT-PCR and qRT-PCR. Total RNA was extracted using Qiagen extraction kits according to the manufacturer's protocol, and cDNAs were generated by reverse transcription using iScript cDNA Synthesis Kit (BioRad) as previously reported 39 . qPCR was performed using fluorogenic SYBR Green and Mx4000 Multiplex Quantitative PCR System (Stratagene) as previously described 39 . GAPDH was used as reference gene in all qRT-PCR reactions. PCR was performed using the primers listed in Supplementary Table 2 at a final concentration of 100 nM. Relative transcript abundance of a gene is expressed in ∆Ct values (∆Ct = Ct reference -Ct target ). Relative changes in transcript levels compared with controls are expressed as ∆∆Ct values (∆∆Ct = ∆Ct treated -∆Ct control ) as previously described 39 .
Western blot analysis. Cells and tissues were harvested, lysed in RIPA buffer (Thermo Scientific) and supplemented with Halt Protease and Phosphatase Inhibitor Cocktail (Thermo Scientific). Protein extracts were subjected to centrifugation (6,000g) at 4 °C, and protein concentrations were determined using BCA assay (Pierce). Protein was separated on either NativePAGE Bis-Tris Gel System or 4-12% SDS-Tris-Glycine Protein Gel. Separated proteins were transferred onto polyvinylidene difluoride (PDVF) membranes (Invitrogen), and membranes were blocked with 5% nonfat dry milk in TBS and incubated with the indicated primary antibodies. After washing, membranes were incubated with appropriate secondary, HRP-linked antibodies (Pierce). Proteins were visualized by enhanced chemiluminescence and autoradiography (ECL; Amersham Biosciences, GE Healthcare).
Immunofluorescence analysis. Cells were plated on glass coverslips, treated with GI254023X (20 nM) or TGF-β as described and fixed with 4% PFA for 10-15 min. The cells were then washed three times with PBS, blocked for one hour in blocking solution (10% goat serum; 0.1% triton-X in PBS) and incubated overnight at 4 °C with a primary antibody against α-SMA (clone 1A4, Sigma-Aldrich; 1:100 in blocking solution). The next day, samples were washed three times with PBS and incubated for one hour with goat anti-mouse Alexa Fluor 488 and rhodamine phalloidin antibodies (Thermo Fisher Scientific) diluted to 1:400 and 1:200, respectively, in blocking solution. Samples were washed three times with PBS and mounted with VECTASHIELD Antifade Mounting Medium with DAPI (Vectorlabs). Images were acquired with a Zeiss LSM780 confocal microscope (Zeiss).
Human plasma samples. Subjects with IPF were identified from those receiving care at the Massachusetts General Hospital. For study inclusion, IPF subjects had to satisfy IPF diagnostic criteria based on the 2011 recent joint consensus statement of the American Thoracic Society (ATS), European Respiratory Society (ERS), Japanese Respiratory Society 41 and Latin American Thoracic Association 41 as determined by two investigators 41 (Supplementary Table 1) . Partners Healthcare System Research Study Volunteer Program (RSVP) was used to recruit controls. Controls were at least 50 years of age and were nonsmokers without a history of chronic lung disease. Approval for plasma collection was obtained through the Partners Institutional Review Board. All subjects provided informed consent. Blood was obtained via venipuncture into tubes containing CTAD (citrate-theophylline-adenosine-dipyridamole). Whole blood was centrifuged at 1,500g for 15 min to obtain plasma, which was then placed in aliquots and immediately frozen and stored at −80 °C until analysis.
Human BAL samples. BAL samples from individuals with IPF and healthy volunteer donors were recovered after instillation of sterile 0.9% saline by flexible fiber-optic bronchoscopy. Bronchoscopies were performed at both the Instituto Nacional de Enfermedades Respiratorias (INER), Mexico and the Massachusetts General Hospital (MGH), as previously described 38 . These studies were approved by the INER Ethics Committee and the MGH Institutional Review Board, and informed consent was obtained from all participants. BAL supernatants that were collected at MGH were immediately transferred to siliconized low-binding Eppendorf tubes, and supernatants from both institutions were kept at −70 °C until use.
Statistical analysis. Sample sizes were determined by power analysis on the basis of our previous studies. In each experiment evaluating the effects of genetic depletion of ephrin-B2 in fibroblasts or ADAM10 inhibition on the extent of dermal and lung fibrosis produced in mice, n ≥ 8 mice per group were used to account for the inherent variability in the fibrotic response of mice. Sample sizes were estimated based on an 80% power to detect a 50% reduction in the amount of fibrosis present in Ephrinb2-CKO mice or mice treated with ADAM10 inhibitor compared with WT control mice, accepting a type I error rate of 0.05. No animals were excluded from analysis. Animals were distributed into groups of equal body weight and genotype before treatments. Experimental data were analyzed by unpaired Student′s t-test for differences between each of the experimental conditions, two-way ANOVA for overall condition effects or log-rank test for differences in survival times using GraphPad Prism Software 5.0. The P values obtained are indicated in the figures and figure legends when statistically significant. *P < 0.05, **P < 0.01, ***P < 0.001 was considered significantly different between groups. All data displayed a normal distribution. Data are reported as mean ± s.d.
Data availability. Data are available from the corresponding authors upon reasonable request. A Life Sciences Reporting Summary for is available.
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Experimental design 1. Sample size
Describe how sample size was determined.
In each experiment evaluating the effects of genetic depletion of ephrin-B2 in fibroblasts on the extent of dermal and lung fibrosis produced in mice, we use > or = 8 mice per group to achieve statistical significance and account for the inherent variability in the fibrotic response of mice. Assuming a 50% reduction in the amount of fibrosis present in ephrin-b2 CKO mice compared with wild-type control mice, then at least 8 mice per group were needed to achieve a power of 80%, accepting a Type I error rate of 0.05. Histological analyses were done using n=8 mice per group. Collagen determinations by hydroxyproline levels were performed using n=6 mice per group. Western blot analyses from our in vivo mouse model of lung fibrosis includes 6 samples per condition. Representative blot shows at least n=4 samples/group. Protein densitometry is also included from n=6 samples per group. Similarly, studies involving injection of recombinant ephrin-B2-Fc in mouse skin include n=6 mice/group. Western blots from 4 individual mice per group are presented.
In each experiment evaluating the effects of a ADAM10 selective inhibitor GI254023X on the extent of lung fibrosis produced in mice, we use > or = 10 mice per group to achieve statistical significance and account for the inherent variability in the fibrotic response of mice. Assuming a 50% reduction in the amount of fibrosis present in mice treated with active drug compared with vehicle control, then 10 mice per group were needed to achieve a power of 80%, accepting a Type I error rate of 0.05. Collagen determinations by hydroxyproline levels were performed using n=8 mice per group. Western blot analyses from our in vivo mouse model of lung fibrosis includes 6 samples per condition. Representative blot shows at least n=3 samples/group. Protein densitometry is also included from n=6 samples per group. Determination of soluble ephrin-B2 levels in BAL fluid was performed using n = 8 mice for all groups.
Data exclusions
Describe any data exclusions. No animals were excluded from the analysis.
Replication
Describe whether the experimental findings were reliably reproduced.
All attempts of replication were successful.
Randomization
Describe how samples/organisms/participants were allocated into experimental groups.
For experiments with control and conditional KO mice, animals were first genotyped and then randomly assigned to receive either bleomycin or PBS. For experiments with IgG and Ephrin B2Fc, wild type C57BL/6N mice were randomly divided in cages of 5 mice/cage who received either IgG or Ephrin B2 Fc. For experiments with ADAM10 inhibitor, all mice used were wild type (C57Bl/6N) animals, and were purchased commercially and randomized to experimental groups by the cages our animal facility put them in upon their arrival from the vendor.
Blinding
Describe whether the investigators were blinded to Blinded analysis was performed for histopathological analysis of skin and lung group allocation during data collection and/or analysis. fibrosis, filopodia quantitation and immunofluorescence studies by two blinded observers.
Note: all studies involving animals and/or human research participants must disclose whether blinding and randomization were used.
Statistical parameters
For all figures and tables that use statistical methods, confirm that the following items are present in relevant figure legends (or in the Methods section if additional space is needed).
n/a Confirmed
The exact sample size ( ) for each experimental group/condition, given as a discrete number and unit of measurement (animals, litters, cultures, etc.)
A description of how samples were collected, noting whether measurements were taken from distinct samples or whether the same sample was measured repeatedly A statement indicating how many times each experiment was replicated
The statistical test(s) used and whether they are one-or two-sided (note: only common tests should be described solely by name; more complex techniques should be described in the Methods section)
A description of any assumptions or corrections, such as an adjustment for multiple comparisons
The test results (e.g. values) given as exact values whenever possible and with confidence intervals noted A clear description of statistics including central tendency (e.g. median, mean) and variation (e.g. standard deviation, interquartile range)
Clearly defined error bars
Software Policy information about availability of computer code
Software
Describe the software used to analyze the data in this study.
GraphPad Prism Software 5.0 was used for unpaired Student's t, Two way ANOVA and log-rank test to determine significance.
For manuscripts utilizing custom algorithms or software that are central to the paper but not yet described in the published literature, software must be made available to editors and reviewers upon request. We strongly encourage code deposition in a community repository (e.g. GitHub). guidance for providing algorithms and software for publication provides further information on this topic.
